338 results
Search Results
2. Integrating Clinical Trials and Practice: A New JAMA Series and Call for Papers.
- Author
-
Curfman G
- Subjects
- Humans, United States, Clinical Trials as Topic standards, Periodicals as Topic
- Published
- 2024
- Full Text
- View/download PDF
3. Improving Women's Health Across the Life Span-JAMA Internal Medicine Call for Papers.
- Author
-
Grady D, Allore HG, Corbie G, Covinsky KE, Durant RW, Ganguli I, Gross CP, Katz MH, Mody L, Wang T, Tripodis Y, and Inouye SK
- Subjects
- Humans, Female, Periodicals as Topic, Women's Health, Internal Medicine
- Published
- 2024
- Full Text
- View/download PDF
4. Prediction Models and Clinical Outcomes-A Call for Papers.
- Author
-
Fihn SD, Berlin JA, Haneuse SJPA, and Rivara FP
- Published
- 2024
- Full Text
- View/download PDF
5. Health and the 2024 Elections Globally-A Call for Papers.
- Author
-
Bibbins-Domingo K, Curfman G, Park H, and Flanagin A
- Subjects
- Politics
- Published
- 2024
- Full Text
- View/download PDF
6. The Bacterial Aspects of Dirty Money.
- Subjects
- *
PAPER money , *BACTERIAL contamination , *DUST , *HYGIENE , *DISEASE vectors - Abstract
The article focuses on the bacterial aspects of dirty money and the historical concern regarding the transmission of infectious material through currency. While previous worries highlighted the potential danger of dirty paper money, bacteriological investigations failed to find significant microbial distribution on paper currency, suggesting that the composition of printed bills might inhibit bacterial growth.
- Published
- 2024
- Full Text
- View/download PDF
7. How to Navigate the Pitfalls of AI Hype in Health Care.
- Author
-
Suran, Melissa and Hswen, Yulin
- Subjects
DATA privacy ,ARTIFICIAL intelligence ,MEDICAL care ,COMPUTER science ,COLLEGE teachers - Abstract
In this Medical News article, Arvind Narayanan, PhD, a professor of computer science at Princeton University, discusses the benefits of using artificial intelligence in research and clinical settings while remaining cautious of hype, biases, and data privacy issues. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. JAMA Pediatrics—The Year in Review, 2023.
- Author
-
Christakis, Dimitri A.
- Published
- 2024
- Full Text
- View/download PDF
9. Aftermath.
- Author
-
Nigliazzo, Stacy R.
- Subjects
MEDICAL periodicals ,MEDICAL societies - Abstract
The poem "Aftermath" by Stacy R. Nigliazzo is presented. First line: Asters reach from paper cups across the nurses' desk. ; Last Line: Some of us cry. All of us get back to work.
- Published
- 2024
- Full Text
- View/download PDF
10. Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of Access.
- Author
-
Underhill, Craig, Freeman, Jessica, Dixon, Jacqueline, Buzza, Mark, Long, Donna, Burbury, Kate, Sabesan, Sabe, McBurnie, Jacqueline, and Woollett, Anne
- Published
- 2024
- Full Text
- View/download PDF
11. Blind Spots, Shortcuts, and Automation Bias—Researchers Are Aiming to Improve AI Clinical Models.
- Author
-
Abbasi, Jennifer and Hswen, Yulin
- Subjects
RESEARCH personnel ,ARTIFICIAL intelligence ,AUTOMATION ,COMPUTER scientists - Abstract
This Medical News article is an interview with University of Michigan computer scientist Jenna Wiens, whose research interests lie at the intersection of AI and health care, and JAMA Editor in Chief Kirsten Bibbins-Domingo. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Citations of microRNA Biomarker Articles That Were Retracted: A Systematic Review.
- Author
-
Zhu, Hongmei, Jia, Yongliang, and Leung, Siu-wai
- Published
- 2024
- Full Text
- View/download PDF
13. Why Wonder Why?
- Author
-
Patel, Jayshil J.
- Published
- 2024
- Full Text
- View/download PDF
14. Rehabilitation.
- Subjects
REHABILITATION ,MEDICAL societies ,FARM life - Abstract
The article underscores the changing dynamics of patient rehabilitation, highlighting the challenges faced by family physicians in urban environments. It emphasizes the critical role of rehabilitation in medical care, advocating for increased attention to this phase of treatment and the integration of physical medicine and occupational therapy.
- Published
- 2024
- Full Text
- View/download PDF
15. Patient Preferences for Telemedicine Video Backgrounds.
- Author
-
Houchens, Nathan, Saint, Sanjay, Kuhn, Latoya, Ratz, David, Engle, Jason M., and Meddings, Jennifer
- Published
- 2024
- Full Text
- View/download PDF
16. Introducing the JAMA Summit.
- Author
-
Bibbins-Domingo, Kirsten, Angus, Derek C., Park, Hannah, Lewis, Roger J., Khera, Rohan, Zeis, Jennifer, Flanagin, Annette, and Curfman, Gregory
- Abstract
The article discusses the JAMA Summit that was held in Chicago, U.S. in October 2023. Topics discussed include the challenges and opportunities to improve the design and conduct of randomized clinical trials, with a focus on making them more responsive to the needs in clinical practice. Attendees included researchers, funders, regulators, patient advocates, policymakers, innovators, and industry representatives.
- Published
- 2024
- Full Text
- View/download PDF
17. Obstacles to Biosimilar Acceptance and Uptake in Oncology: A Review.
- Author
-
Mroczek, Daniel K., Hauner, Katherina, Greene, George J., Kaiser, Karen, Peipert, John Devin, Golf, Mary, Kircher, Sheetal, Shaunfield, Sara, Lylerohr, Madison, and Cella, David
- Published
- 2024
- Full Text
- View/download PDF
18. Coaches Activating, Reaching, and Engaging Patients to Engage in Advance Care Planning: A Randomized Clinical Trial.
- Author
-
Rodriguez, Gladys M., Parikh, Divya A., Kapphahn, Kris, Gupta, Divya M., Fan, Alice C., Shah, Sumit, Srinivas, Sandy, Teuteberg, Winifred, Seevaratnam, Briththa, Asuncion, Khay, Chien, Joanne, Moore, Kaidi, Ruiz, Shann Mika, and Patel, Manali I.
- Published
- 2024
- Full Text
- View/download PDF
19. Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
- Author
-
Kopmar, Noam E., Quach, Kim, Gooley, Ted A., Martino, Christen H., Cherian, Sindhu, Percival, Mary-Elizabeth M., Halpern, Anna B., Ghiuzeli, Cristina M., Oehler, Vivian G., Abkowitz, Janis L., Walter, Roland B., and Cassaday, Ryan D.
- Published
- 2024
- Full Text
- View/download PDF
20. Antibiotic Prophylaxis and Infective Endocarditis Incidence Following Invasive Dental Procedures: A Systematic Review and Meta-Analysis.
- Author
-
Sperotto, Francesca, France, Katherine, Gobbo, Margherita, Bindakhil, Mohammed, Pimolbutr, Kununya, Holmes, Haly, Monteiro, Luis, Graham, Laurel, Hong, Catherine H. L., Sollecito, Thomas P., Lodi, Giovanni, Lockhart, Peter B., Thornhill, Martin, Diz Dios, Pedro, Turati, Federica, and Edefonti, Valeria
- Published
- 2024
- Full Text
- View/download PDF
21. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial.
- Author
-
Gaudet, Daniel, Pall, Denes, Watts, Gerald F., Nicholls, Stephen J., Rosenson, Robert S., Modesto, Karen, San Martin, Javier, Hellawell, Jennifer, and Ballantyne, Christie M.
- Published
- 2024
- Full Text
- View/download PDF
22. How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice?
- Author
-
Edens, Ellen L., Vassallo, Gabriela Garcia, and Heimer, Robert
- Subjects
NARCOTIC laws ,DRUG control ,SUBSTANCE abuse ,CONTINUING education units ,MEDICAL protocols ,MEDICAL prescriptions ,CHRONIC diseases ,NARCOTICS ,PHYSICIAN practice patterns ,PAIN ,DRUG prescribing ,TERMINAL care - Abstract
This article describes historical and political reasons for--and devastating consequences of--US opioid prescribing policy since the 1990s, which has restricted opioid prescribing for pain less than for treating opioid use disorder (OUD) treatment. This article considers merits and drawbacks of a new diagnostic category and proposes a regulatory and clinical framework for prescribing long-term opioid therapy for pain and for prescribing opioids to treat OUD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. How Should Harm Reduction Strategies Differ for Adolescents and Adults?
- Author
-
Heward, Brady J., Yule, Amy M., and Jackson, Peter R.
- Subjects
SUBSTANCE abuse ,CONTINUING education units ,ADOLESCENT development ,AUTONOMY (Psychology) ,PRIVACY ,HARM reduction ,NARCOTICS ,EVIDENCE-based medicine ,SOCIAL support ,MEDICAL ethics ,ADOLESCENCE ,ADULTS - Abstract
Overall rates of opioid use are low in adolescents; however, recent increases in mortality from overdose in adolescents have outpaced increases in the general population. This article highlights the importance of expanding evidence-based treatment for adolescent opioid use, especially medication, while also addressing key ethical considerations of harm reduction practices and how application of such practices with adolescents may differ from adults. Concepts related to adolescent populations are discussed, including autonomy, confidentiality, and brain development. Application of harm reduction practices should be age appropriate, express respect for patients' autonomy, include social support, and be accompanied by broader aims to minimize adolescent initiation, escalation, and overall harm caused by opioid use. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening: A Systematic Review and Meta-Analysis.
- Author
-
Feng, Xiaoshuang, Zahed, Hana, Onwuka, Justina, Callister, Matthew E. J., Johansson, Mattias, Etzioni, Ruth, and Robbins, Hilary A.
- Subjects
CLINICAL trials ,EARLY detection of cancer ,TUMOR classification ,PROSTATE cancer ,MORTALITY ,SIGMOIDOSCOPY ,MEDICAL screening - Abstract
Key Points: Question: Compared with the end point of cancer-specific mortality, is incidence of late-stage cancer a suitable alternative end point in randomized clinical trials of cancer screening? Findings: In this systematic review and meta-analysis that included 41 randomized clinical trials of cancer screening, correlation between the reduction in stage III and IV cancer and the reduction in cancer-specific mortality varied by cancer type. The correlation was high in trials that screened for ovarian (Pearson ρ = 0.99) and lung (Pearson ρ = 0.92) cancers, moderate for breast cancer (Pearson ρ = 0.70), and weak for colorectal (Pearson ρ = 0.39) and prostate (Pearson ρ = −0.69) cancers. Meaning: In randomized clinical trials of cancer screening, the correlation between reductions in late-stage cancer and cancer-specific mortality varied meaningfully by cancer type. The end point of late-stage cancer may be an appropriate alternative to cancer-specific mortality for randomized clinical trials of screening for some types of cancer, but not for others. Importance: Randomized clinical trials of cancer screening typically use cancer-specific mortality as the primary end point. The incidence of stage III-IV cancer is a potential alternative end point that may accelerate completion of randomized clinical trials of cancer screening. Objective: To compare cancer-specific mortality with stage III-IV cancer as end points in randomized clinical trials of cancer screening. Design, Setting, and Participants: This meta-analysis included 41 randomized clinical trials of cancer screening conducted in Europe, North America, and Asia published through February 19, 2024. Data extracted included numbers of participants, cancer diagnoses, and cancer deaths in the intervention and comparison groups. For each clinical trial, the effect of screening was calculated as the percentage reduction between the intervention and comparison groups in the incidence of participants with cancer-specific mortality and stage III-IV cancer. Exposures: Randomization to a cancer screening test or to a comparison group in a clinical trial of cancer screening. Main Outcomes and Measures: End points of cancer-specific mortality and incidence of stage III-IV cancer were compared using Pearson correlation coefficients with 95% CIs, linear regression, and fixed-effects meta-analysis. Results: The included randomized clinical trials tested benefits of screening for breast (n = 6), colorectal (n = 11), lung (n = 12), ovarian (n = 4), prostate (n = 4), and other cancers (n = 4). Correlation between reductions in cancer-specific mortality and stage III-IV cancer varied by cancer type (I
2 = 65%; P =.02). Correlation was highest for trials that screened for ovarian (Pearson ρ = 0.99 [95% CI, 0.51-1.00]) and lung (Pearson ρ = 0.92 [95% CI, 0.72-0.98]) cancers, moderate for breast cancer (Pearson ρ = 0.70 [95% CI, −0.26 to 0.96]), and weak for colorectal (Pearson ρ = 0.39 [95% CI, −0.27 to 0.80]) and prostate (Pearson ρ = −0.69 [95% CI, −0.99 to 0.81]) cancers. Slopes from linear regression were estimated as 1.15 for ovarian cancer, 0.75 for lung cancer, 0.40 for colorectal cancer, 0.28 for breast cancer, and −3.58 for prostate cancer, suggesting that a given magnitude of reduction in incidence of stage III-IV cancer produced different magnitudes of change in incidence of cancer-specific mortality (P for heterogeneity =.004). Conclusions and Relevance: In randomized clinical trials of cancer screening, incidence of late-stage cancer may be a suitable alternative end point to cancer-specific mortality for some cancer types, but is not suitable for others. These results have implications for clinical trials of multicancer screening tests. This meta-analysis of 41 randomized clinical trials of cancer screening compares cancer-specific mortality with stage III-IV cancer as end points. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
25. Causal Inference About the Effects of Interventions From Observational Studies in Medical Journals.
- Author
-
Dahabreh, Issa J. and Bibbins-Domingo, Kirsten
- Subjects
MEDICAL periodicals ,CAUSAL inference ,SCIENTIFIC observation ,CLINICAL trials ,HEALTH policy - Abstract
Importance: Many medical journals, including JAMA, restrict the use of causal language to the reporting of randomized clinical trials. Although well-conducted randomized clinical trials remain the preferred approach for answering causal questions, methods for observational studies have advanced such that causal interpretations of the results of well-conducted observational studies may be possible when strong assumptions hold. Furthermore, observational studies may be the only practical source of information for answering some questions about the causal effects of medical or policy interventions, can support the study of interventions in populations and settings that reflect practice, and can help identify interventions for further experimental investigation. Identifying opportunities for the appropriate use of causal language when describing observational studies is important for communication in medical journals. Observations: A structured approach to whether and how causal language may be used when describing observational studies would enhance the communication of research goals, support the assessment of assumptions and design and analytic choices, and allow for more clear and accurate interpretation of results. Building on the extensive literature on causal inference across diverse disciplines, we suggest a framework for observational studies that aim to provide evidence about the causal effects of interventions based on 6 core questions: what is the causal question; what quantity would, if known, answer the causal question; what is the study design; what causal assumptions are being made; how can the observed data be used to answer the causal question in principle and in practice; and is a causal interpretation of the analyses tenable? Conclusions and Relevance: Adoption of the proposed framework to identify when causal interpretation is appropriate in observational studies promises to facilitate better communication between authors, reviewers, editors, and readers. Practical implementation will require cooperation between editors, authors, and reviewers to operationalize the framework and evaluate its effect on the reporting of empirical research. This Special Communication examines drawing causal inferences about the effects of interventions from observational studies in medical journals. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Cardiovascular Burden of the V142I Transthyretin Variant.
- Author
-
Selvaraj, Senthil, Claggett, Brian, Shah, Svati H., Mentz, Robert J., Khouri, Michel G., Manichaikul, Ani W., Khan, Sadiya S., Rich, Stephen S., Mosley, Thomas H., Levitan, Emily B., Arora, Pankaj, Goyal, Parag, Haring, Bernhard, Eaton, Charles B., Cheng, Richard K., Wells, Gretchen L., Manson, JoAnn E., Fontana, Marianna, and Solomon, Scott D.
- Subjects
HEART failure ,TRANSTHYRETIN ,NATURAL history ,BLACK people ,RACE ,DISEASE vectors - Abstract
Key Points: Question: What is the natural history and cardiovascular burden of the V142I variant of the transthyretin (TTR) gene among US Black carriers across mid to late life? Findings: Across 4 cohort studies, carriers (754/23 338) faced a substantially increased risk for heart failure (by age 63 years) and death (by age 72 years), similarly in men and women, which was estimated to contribute to approximately 1 million years of life lost among US Black individuals aged ≥50 years. Meaning: These data show the large, age-dependent burden of V142I, which may guide discussions regarding the initiation and results of genetic screening, provide clinicians with risk estimates to share with patients, and inform strategies for early targeted therapy. Importance: Individual cohort studies concur that the amyloidogenic V142I variant of the transthyretin (TTR) gene, present in 3% to 4% of US Black individuals, increases heart failure (HF) and mortality risk. Precisely defining carrier risk across relevant clinical outcomes and estimating population burden of disease are important given established and emerging targeted treatments. Objectives: To better define the natural history of disease in carriers across mid to late life, assess variant modifiers, and estimate cardiovascular burden to the US population. Design, Setting, and Participants: A total of 23 338 self-reported Black participants initially free from HF were included in 4 large observational studies across the US (mean [SD], 15.5 [8.2] years of follow-up). Data analysis was performed between May 2023 and February 2024. Exposure: V142I carrier status (n = 754, 3.2%). Main Outcomes and Measures: Hospitalizations for HF (including subtypes of reduced and preserved ejection fraction) and all-cause mortality. Outcomes were analyzed by generating 10-year hazard ratios for each age between 50 and 90 years. Using actuarial methods, mean survival by carrier status was estimated and applied to the 2022 US population using US Census data. Results: Among the 23 338 participants, the mean (SD) age at baseline was 62 (9) years and 76.7% were women. Ten-year carrier risk increased for HF hospitalization by age 63 years, predominantly driven by HF with reduced ejection fraction, and 10-year all-cause mortality risk increased by age 72 years. Only age (but not sex or other select variables) modified risk with the variant, with estimated reductions in longevity ranging from 1.9 years (95% CI, 0.6-3.1) at age 50 to 2.8 years (95% CI, 2.0-3.6) at age 81. Based on these data, 435 851 estimated US Black carriers between ages 50 and 95 years are projected to cumulatively lose 957 505 years of life (95% CI, 534 475-1 380 535) due to the variant. Conclusions and Relevance: Among self-reported Black individuals, male and female V142I carriers faced similar and substantial risk for HF hospitalization, predominantly with reduced ejection fraction, and death, with steep age-dependent penetrance. Delineating the individual contributions of, and complex interplay among, the V142I variant, ancestry, the social construct of race, and biological or social determinants of health to cardiovascular disease merits further investigation. This study used data on Black participants in 4 large observational studies to better define the natural history of disease in V142I variant carriers across mid to late life, assess variant modifiers, and estimate cardiovascular burden to the US population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. A Multimodal Video-Based AI Biomarker for Aortic Stenosis Development and Progression.
- Author
-
Oikonomou, Evangelos K., Holste, Gregory, Yuan, Neal, Coppi, Andreas, McNamara, Robert L., Haynes, Norrisa A., Vora, Amit N., Velazquez, Eric J., Li, Fan, Menon, Venu, Kapadia, Samir R., Gill, Thomas M., Nadkarni, Girish N., Krumholz, Harlan M., Wang, Zhangyang, Ouyang, David, and Khera, Rohan
- Published
- 2024
- Full Text
- View/download PDF
28. Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical Trial.
- Author
-
Peikert, Alexander, Claggett, Brian L., Udell, Jacob A., Joseph, Jacob, Hegde, Sheila M., Kim, KyungMann, Mao, Lu, Wang, Tuo, Havighurst, Thomas C., Farkouh, Michael E., Bhatt, Deepak L., Tattersall, Matthew C., Cooper, Lawton S., Solomon, Scott D., and Vardeny, Orly
- Published
- 2024
- Full Text
- View/download PDF
29. Relaxation Therapy and Human Milk Feeding Outcomes: A Systematic Review and Meta-Analysis.
- Author
-
Levene, Ilana, Mohd Shukri, Nurul Husna, O'Brien, Frances, Quigley, Maria A., and Fewtrell, Mary
- Published
- 2024
- Full Text
- View/download PDF
30. Reconstruction for Salvage Laryngectomy With Limited Pharyngectomy.
- Author
-
Moreno, Mauricio A., Wax, Mark K., Gardner, James Reed, Cannady, Steven B., Graboyes, Evan M., Bewley, Arnaoud F., Dziegielewski, Peter T., Khaja, Sobia F., Bayon, Rodrigo, Ryan, Jesse, Al-Khudari, Samer, El-Deiry, Mark W., Ghanem, Tamer A., Huang, Andrew, Patel, Rusha, Higgins, Kevin M., Jackson, Ryan S., and Patel, Urjeet A.
- Published
- 2024
- Full Text
- View/download PDF
31. Home-Monitoring Vision Tests to Detect Active Neovascular Age-Related Macular Degeneration.
- Author
-
Hogg, Ruth E., Sivaprasad, Sobha, Wickens, Robin, O'Connor, Sean, Gidman, Eleanor, Ward, Elizabeth, Treanor, Charlene, Peto, Tunde, Burton, Ben J. L., Knox, Paul, Lotery, Andrew J., Donnelly, Michael, Rogers, Chris A., and Reeves, Barnaby C.
- Published
- 2024
- Full Text
- View/download PDF
32. Patching in Children With Unilateral Congenital Cataract and Child Functioning and Parenting Stress.
- Author
-
Drews-Botsch, Carolyn, Cotsonis, George, Celano, Marianne, Hartmann, E. Eugenie, Zaidi, Jaffer, and Lambert, Scott R.
- Published
- 2024
- Full Text
- View/download PDF
33. Association of New-Onset Seizures With SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
- Author
-
Rafati, Ali, Jameie, Melika, Amanollahi, Mobina, Pasebani, Yeganeh, Jameie, Mana, Kabiri, Ali, Montazeri Namin, Sara, Sakhaei, Delaram, Feizollahi, Fateme, Pasebani, Mohammad Yazdan, Mohebbi, Hossein, Ilkhani, Saba, Azadi, Mohammadreza, Rahimlou, Mehran, and Kwon, Churl-Su
- Published
- 2024
- Full Text
- View/download PDF
34. Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders.
- Author
-
Paller, Amy S., Rangel, Stephanie M., Chamlin, Sarah L., Hajek, Aleena, Phan, Sheshanna, Hogeling, Marcia, Castelo-Soccio, Leslie, Lara-Corrales, Irene, Arkin, Lisa, Lawley, Leslie P., Funk, Tracy, Castro Porto Silva Lopes, Fabiana, Antaya, Richard J., Ramien, Michele L., Vivar, Karina L., Teng, Joyce, Coughlin, Carrie C., Rehmus, Wingfield, Gupta, Deepti, and Bercovitch, Lionel
- Published
- 2024
- Full Text
- View/download PDF
35. Essentials of Informed Consent to Psychedelic Medicine.
- Author
-
Marks, Mason, Brendel, Rebecca W., Shachar, Carmel, and Cohen, I. Glenn
- Subjects
MENTAL health services ,HALLUCINOGENIC drugs ,PATIENT abuse ,LAW reform ,PERSONALITY change ,PSYCHIATRIC nursing - Abstract
This Special Communication discusses the essential elements of designing and implementing informed consent practices for psychedelic medicine. Importance: Interest in administering psychedelic agents as mental health treatment is growing rapidly. As drugmakers invest in developing psychedelic medicines for several psychiatric indications, lawmakers are enacting legal reforms to speed access globally, and health agencies are preparing to approve these treatments. Meanwhile, US states, such as Oregon and Colorado, are making psychedelics available for supervised use outside the conventional health care system. Observations: Despite legal change and potentially imminent regulatory approval in some countries, standards for integrating psychedelics into health care have lagged, including norms for designing and implementing informed consent processes. Informed consent is complicated by the unique features of psychedelics and their means of administration. Because no governments have approved any classic psychedelics for general medical or psychiatric use, only clinical researchers have obtained informed consent from trial participants. Accordingly, there is an unmet need for informed consent processes tailored to the challenges of administering psychedelics in nonresearch settings. Conclusions and Relevance: Analysis of the challenges of designing and implementing psychedelic informed consent practices revealed 7 essential components, including the possibility of short- and long-term perceptual disturbances, potential personality changes and altered metaphysical beliefs, the limited role of reassuring physical touch, the potential for patient abuse or coercion, the role and risks of data collection, relevant practitioner disclosures, and interactive patient education and comprehension assessment. Because publicly available informed consent documents for psychedelic clinical trials often overlook or underemphasize these essential elements, sample language and procedures to fill the gap are proposed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. How Should We Think About Clinicians' Individual Antibiotic Stewardship Duties?
- Author
-
Rieder, Travis N. and Modlin, Chelsea
- Subjects
MEDICAL personnel ,ANTIMICROBIAL stewardship ,DRUG resistance in microorganisms ,PRIMARY health care ,BIOETHICS ,EXPERTISE - Abstract
The language of antibiotic stewardship is often used to capture the moral importance of individual prescribers doing their part to combat antibiotic resistance. "Stewardship" as an ethics concept borrows from collective action problems--those that cannot be solved by individuals only--like those discussed in the environmental ethics literature. This article suggests that hyper focus on stewardship, however, risks misunderstanding individual prescribers' reasons to limit antibiotic use. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Year-Over-Year Ventral Hernia Recurrence Rates and Risk Factors.
- Author
-
Bhardwaj, Priya, Huayllani, Maria T., Olson, Molly A., and Janis, Jeffrey E.
- Published
- 2024
- Full Text
- View/download PDF
38. Cost-Effectiveness of Parathyroid Cryopreservation and Autotransplantation.
- Author
-
Frye, C. Corbin, Sullivan, Janessa, Sanka, Sai Anusha, Smith, Eileen R., Goetz, Brian, Brunt, L. Michael, Gillanders, William, Brown, Taylor C., Olson, John A., Hall, Bruce, and Pandian, T. K.
- Published
- 2024
- Full Text
- View/download PDF
39. The Women's Health Initiative Randomized Trials and Clinical Practice: A Review.
- Author
-
Manson, JoAnn E., Crandall, Carolyn J., Rossouw, Jacques E., Chlebowski, Rowan T., Anderson, Garnet L., Stefanick, Marcia L., Aragaki, Aaron K., Cauley, Jane A., Wells, Gretchen L., LaCroix, Andrea Z., Thomson, Cynthia A., Neuhouser, Marian L., Van Horn, Linda, Kooperberg, Charles, Howard, Barbara V., Tinker, Lesley F., Wactawski-Wende, Jean, Shumaker, Sally A., and Prentice, Ross L.
- Subjects
WOMEN'S health ,MEDITERRANEAN diet ,HORMONE therapy for menopause ,CLINICAL trials ,LOW-fat diet ,DIETARY patterns ,TRIAL practice ,SOFT drinks - Abstract
Importance: Approximately 55 million people in the US and approximately 1.1 billion people worldwide are postmenopausal women. To inform clinical practice about the health effects of menopausal hormone therapy, calcium plus vitamin D supplementation, and a low-fat dietary pattern, the Women's Health Initiative (WHI) enrolled 161 808 postmenopausal US women (N = 68 132 in the clinical trials) aged 50 to 79 years at baseline from 1993 to 1998, and followed them up for up to 20 years. Observations: The WHI clinical trial results do not support hormone therapy with oral conjugated equine estrogens plus medroxyprogesterone acetate for postmenopausal women or conjugated equine estrogens alone for those with prior hysterectomy to prevent cardiovascular disease, dementia, or other chronic diseases. However, hormone therapy is effective for treating moderate to severe vasomotor and other menopausal symptoms. These benefits of hormone therapy in early menopause, combined with lower rates of adverse effects of hormone therapy in early compared with later menopause, support initiation of hormone therapy before age 60 years for women without contraindications to hormone therapy who have bothersome menopausal symptoms. The WHI results do not support routinely recommending calcium plus vitamin D supplementation for fracture prevention in all postmenopausal women. However, calcium and vitamin D are appropriate for women who do not meet national guidelines for recommended intakes of these nutrients through diet. A low-fat dietary pattern with increased fruit, vegetable, and grain consumption did not prevent the primary outcomes of breast or colorectal cancer but was associated with lower rates of the secondary outcome of breast cancer mortality during long-term follow-up. Conclusions and Relevance: For postmenopausal women, the WHI randomized clinical trials do not support menopausal hormone therapy to prevent cardiovascular disease or other chronic diseases. Menopausal hormone therapy is appropriate to treat bothersome vasomotor symptoms among women in early menopause, without contraindications, who are interested in taking hormone therapy. The WHI evidence does not support routine supplementation with calcium plus vitamin D for menopausal women to prevent fractures or a low-fat diet with increased fruits, vegetables, and grains to prevent breast or colorectal cancer. A potential role of a low-fat dietary pattern in reducing breast cancer mortality, a secondary outcome, warrants further study. This review of the Women's Health Initiative (WHI) summarizes the results of the 4 WHI clinical trials on menopausal hormone therapy, calcium plus vitamin D supplementation, and low-fat diet and their applications to current clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Youth Experiencing Parental Death Due to Drug Poisoning and Firearm Violence in the US, 1999-2020.
- Author
-
Schlüter, Benjamin-Samuel, Alburez-Gutierrez, Diego, Bibbins-Domingo, Kirsten, Alexander, Monica J., and Kiang, Mathew V.
- Subjects
PARENTAL death ,DRUG toxicity ,FIREARMS ,DRUG overdose ,BLACK youth - Abstract
Key Points: Question: What are the estimated rates of US youth (younger than 18 years) who have lost a parent due to drug poisoning or firearms? Findings: In this cross-sectional study of the US population using publicly available data between 1999 and 2020, an estimated 1.19 million US youth had a parent die by drug poisoning or firearms. In 2020, drugs and firearms caused 23% of all parental deaths compared with 12% in 1999, and Black youth experienced a disproportionate burden, mainly due to firearm deaths of fathers. Meaning: Results of this modeling study suggest that US youth are at high and increasing risk of experiencing parental death by drugs or firearms. Importance: Youth (those aged <18 years) parental death has been associated with negative health outcomes. Understanding the burden of parental death due to drug poisoning (herein, drugs) and firearms is essential for informing interventions. Objective: To estimate the incidence of youth parental death due to drugs, firearms, and all other causes. Design, Setting, and Participants: This cross-sectional observational study was conducted using vital registration, including all US decedents, and census data from January 1990 through December 2020. Data were analyzed from May 30, 2023, to March 28, 2024. Exposures: Parental death due to drug poisoning or firearms. Main Outcomes and Measures: A demographic matrix projection model was used to estimate the number and incidence of youth experiencing parental death, defined as the death of 1 or more parents, per 1000 population aged less than 18 years. Analyses evaluated parental deaths by drugs, firearms, and all other causes from 1999 through 2020 by race and ethnicity. Results: Between 1999 and 2020, there were 931 785 drug poisoning deaths and 736 779 firearm-related deaths with a mean (SD) age of 42.6 (16.3) years. Most deaths occurred among males (73.8%) and White decedents (70.8%) followed by Black (17.5%) and Hispanic (9.5%) decedents. An estimated 759 000 (95% CI, 722 000-800 000) youth experienced parental death due to drugs and an estimated 434 000 (95% CI, 409 000-460 000) youth experienced parental death due to firearms, accounting for 17% of all parental deaths. From 1999 to 2020, the estimated number of youth who experienced parental death increased 345% (95% CI, 334%-361%) due to drugs and 39% (95% CI, 37%-41%) due to firearms compared with 24% (95% CI, 23%-25%) due to all other causes. Black youth experienced a disproportionate burden of parental deaths, based primarily on firearm deaths among fathers. In 2020, drugs and firearms accounted for 23% of all parental deaths, double the proportion in 1999 (12%). Conclusions and Relevance: Results of this modeling study suggest that US youth are at high and increasing risk of experiencing parental death by drugs or firearms. Efforts to stem this problem should prioritize averting drug overdoses and firearm violence, especially among structurally marginalized groups. This cross-sectional study uses a demographic projection model and publicly available vital statistics data to estimate the national incidence of parental death due to drugs and firearms overall and by race and ethnicity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Racial and Ethnic Disparities in All-Cause and Cause-Specific Mortality Among US Youth.
- Author
-
Wolf, Elizabeth R., Rivara, Frederick P., Orr, Colin J., Sen, Anabeel, Chapman, Derek A., and Woolf, Steven H.
- Subjects
WHITE youth ,INDIGENOUS youth ,MORTALITY ,BLACK youth ,RACE - Abstract
Key Points: Question: What causes of death are associated with the widening disparities in mortality among US youth of different races and ethnicities in recent years? Findings: In this cross-sectional study of mortality in youth aged 1 to 19 years in the US, injuries, especially firearm injuries, were associated with worsening disparities between Black and American Indian or Alaska Native and White youth. Between 2016 and 2020, the homicide rate in Black youth was 12.81 per 100 000 youth (rate ratio with White youth, 10.20), and the suicide rate for American Indian or Alaska Native youth was 11.37 per 100 000 youth (rate ratio with White youth, 2.60). Meaning: In this study, racial and ethnic disparities were observed for almost all leading causes of injury and disease and were associated with recent increases in US mortality rates. Importance: Mortality rates in US youth have increased in recent years. An understanding of the role of racial and ethnic disparities in these increases is lacking. Objective: To compare all-cause and cause-specific mortality trends and rates among youth with Hispanic ethnicity and non-Hispanic American Indian or Alaska Native, Asian or Pacific Islander, Black, and White race. Design, Setting, and Participants: This cross-sectional study conducted temporal analysis (1999-2020) and comparison of aggregate mortality rates (2016-2020) for youth aged 1 to 19 years using US Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database. Data were analyzed from June 30, 2023, to January 17, 2024. Main Outcomes and Measures: Pooled, all-cause, and cause-specific mortality rates per 100 000 youth (hereinafter, per 100 000) for leading underlying causes of death were compared. Injuries were classified by mechanism and intent. Results: Between 1999 and 2020, there were 491 680 deaths among US youth, including 8894 (1.8%) American Indian or Alaska Native, 14 507 (3.0%) Asian or Pacific Islander, 110 154 (22.4%) Black, 89 251 (18.2%) Hispanic, and 267 452 (54.4%) White youth. Between 2016 and 2020, pooled all-cause mortality rates were 48.79 per 100 000 (95% CI, 46.58-51.00) in American Indian or Alaska Native youth, 15.25 per 100 000 (95% CI, 14.75-15.76) in Asian or Pacific Islander youth, 42.33 per 100 000 (95% CI, 41.81-42.86) in Black youth, 21.48 per 100 000 (95% CI, 21.19-21.77) in Hispanic youth, and 24.07 per 100 000 (95% CI, 23.86-24.28) in White youth. All-cause mortality ratios compared with White youth were 2.03 (95% CI, 1.93-2.12) among American Indian or Alaska Native youth, 0.63 (95% CI, 0.61-0.66) among Asian or Pacific Islander youth, 1.76 (95% CI, 1.73-1.79) among Black youth, and 0.89 (95% CI, 0.88-0.91) among Hispanic youth. From 2016 to 2020, the homicide rate in Black youth was 12.81 (95% CI, 12.52-13.10) per 100 000, which was 10.20 (95% CI, 9.75-10.66) times that of White youth. The suicide rate for American Indian or Alaska Native youth was 11.37 (95% CI, 10.30-12.43) per 100 000, which was 2.60 (95% CI, 2.35-2.86) times that of White youth. The firearm mortality rate for Black youth was 12.88 (95% CI, 12.59-13.17) per 100 000, which was 4.14 (95% CI, 4.00-4.28) times that of White youth. American Indian or Alaska Native youth had a firearm mortality rate of 6.67 (95% CI, 5.85-7.49) per 100 000, which was 2.14 (95% CI, 1.88- 2.43) times that of White youth. Black youth had an asthma mortality rate of 1.10 (95% CI, 1.01-1.18) per 100 000, which was 7.80 (95% CI, 6.78-8.99) times that of White youth. Conclusions and Relevance: In this study, racial and ethnic disparities were observed for almost all leading causes of injury and disease that were associated with recent increases in youth mortality rates. Addressing the increasing disparities affecting American Indian or Alaska Native and Black youth will require efforts to prevent homicide and suicide, especially those events involving firearms. This cross-sectional study compares all-cause and cause-specific mortality trends and rates among youth from different races and ethnicities between 1999 and 2021. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Interstitial Lung Disease: A Review.
- Author
-
Maher, Toby M.
- Subjects
INTERMITTENT claudication ,INTERSTITIAL lung diseases ,HYPERSENSITIVITY pneumonitis ,IDIOPATHIC pulmonary fibrosis ,PULMONARY fibrosis ,VITAL capacity (Respiration) ,CONNECTIVE tissue diseases - Abstract
Importance: Interstitial lung disease (ILD) consists of a group of pulmonary disorders characterized by inflammation and/or fibrosis of the lung parenchyma associated with progressive dyspnea that frequently results in end-stage respiratory failure. In the US, ILD affects approximately 650 000 people and causes approximately 25 000 to 30 000 deaths per year. Observations: The most common forms of ILD are idiopathic pulmonary fibrosis (IPF), which accounts for approximately one-third of all cases of ILD, hypersensitivity pneumonitis, accounting for 15% of ILD cases, and connective tissue disease (CTD), accounting for 25% of ILD cases. ILD typically presents with dyspnea on exertion. Approximately 30% of patients with ILD report cough. Thoracic computed tomography is approximately 91% sensitive and 71% specific for diagnosing subtypes of ILDs such as IPF. Physiologic assessment provides important prognostic information. A 5% decline in forced vital capacity (FVC) over 12 months is associated with an approximately 2-fold increase in mortality compared with no change in FVC. Antifibrotic therapy with nintedanib or pirfenidone slows annual FVC decline by approximately 44% to 57% in individuals with IPF, scleroderma associated ILD, and in those with progressive pulmonary fibrosis of any cause. For connective tissue disease–associated ILD, immunomodulatory therapy, such as tocilizumab, rituximab, and mycophenolate mofetil, may slow decline or even improve FVC at 12-month follow-up. Structured exercise therapy reduces symptoms and improves 6-minute walk test distance in individuals with dyspnea. Oxygen reduces symptoms and improves quality of life in individuals with ILD who desaturate below 88% on a 6-minute walk test. Lung transplant may improve symptoms and resolve respiratory failure in patients with end-stage ILD. After lung transplant, patients with ILD have a median survival of 5.2 to 6.7 years compared with a median survival of less than 2 years in patients with advanced ILD who do not undergo lung transplant. Up to 85% of individuals with end-stage fibrotic ILD develop pulmonary hypertension. In these patients, treatment with inhaled treprostinil improves walking distance and respiratory symptoms. Conclusions and Relevance: Interstitial lung disease typically presents with dyspnea on exertion and can progress to respiratory failure. First-line therapy includes nintedanib or pirfenidone for IPF and mycophenolate mofetil for ILD due to connective tissue disease. Lung transplant should be considered for patients with advanced ILD. In patients with ILD, exercise training improves 6-minute walk test distance and quality of life. This review summarizes current evidence regarding the diagnosis and treatment of interstitial lung disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Systemic Lupus Erythematosus: A Review.
- Author
-
Siegel, Caroline H. and Sammaritano, Lisa R.
- Abstract
Importance: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by inflammation and immune-mediated injury to multiple organ systems, including the mucocutaneous, musculoskeletal, hematologic, and kidney systems. Approximately 3.4 million people worldwide have received a diagnosis of SLE. Observations: Approximately 90% of people with SLE are female. Although there are no uniformly accepted diagnostic criteria for SLE, the 2019 European Alliance of Associations for Rheumatology (formerly the European League Against Rheumatism)/American College of Rheumatology classification criteria developed for scientific study are an estimated 96.1% sensitive and 93.4% specific for SLE. These classification criteria include both clinical factors, such as fever, cytopenia, rash, arthritis, and proteinuria, which may be indicative of lupus nephritis; and immunologic measures, such as SLE-specific autoantibodies and low complement levels. Approximately 40% of people with SLE develop lupus nephritis, and an estimated 10% of people with lupus nephritis develop end-stage kidney disease after 10 years. The primary goal of treatment is to achieve disease remission or quiescence, defined by minimal symptoms, low levels of autoimmune inflammatory markers, and minimal systemic glucocorticoid requirement while the patient is treated with maintenance doses of immunomodulatory or immunosuppressive medications. Treatment goals include reducing disease exacerbations, hospitalizations, and organ damage due to the disease or treatment toxicity. Hydroxychloroquine is standard of care for SLE and has been associated with a significant reduction in mortality. Treatments in addition to hydroxychloroquine are individualized, with immunosuppressive agents, such as azathioprine, mycophenolate mofetil, and cyclophosphamide, typically used for treating moderate to severe disease. Three SLE medications were recently approved by the Food and Drug Administration: belimumab (for active SLE in 2011 and for lupus nephritis in 2020), voclosporin (for lupus nephritis), and anifrolumab (for active SLE). Conclusions and Relevance: Systemic lupus erythematosus is associated with immune-mediated damage to multiple organs and increased mortality. Hydroxychloroquine is first-line therapy and reduces disease activity, morbidity, and mortality. When needed, additional immunosuppressive and biologic therapies include azathioprine, mycophenolate mofetil, cyclophosphamide, belimumab, voclosporin, and anifrolumab. This review summarizes current evidence regarding the diagnosis, treatment, and prognosis of systemic lupus erythematosus. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
- Author
-
Auvinen, Anssi, Tammela, Teuvo L. J., Mirtti, Tuomas, Lilja, Hans, Tolonen, Teemu, Kenttämies, Anu, Rinta-Kiikka, Irina, Lehtimäki, Terho, Natunen, Kari, Nevalainen, Jaakko, Raitanen, Jani, Ronkainen, Johanna, van der Kwast, Theodorus, Riikonen, Jarno, Pétas, Anssi, Matikainen, Mika, Taari, Kimmo, Kilpeläinen, Tuomas, and Rannikko, Antti S.
- Abstract
Importance: Prostate-specific antigen (PSA) screening has potential to reduce prostate cancer mortality but frequently detects prostate cancer that is not clinically important. Objective: To describe rates of low-grade (grade group 1) and high-grade (grade groups 2-5) prostate cancer identified among men invited to participate in a prostate cancer screening protocol consisting of a PSA test, a 4-kallikrein panel, and a magnetic resonance imaging (MRI) scan. Design, Setting, and Participants: The ProScreen trial is a clinical trial conducted in Helsinki and Tampere, Finland, that randomized 61 193 men aged 50 through 63 years who were free of prostate cancer in a 1:3 ratio to either be invited or not be invited to undergo screening for prostate cancer between February 2018 and July 2020. Interventions: Participating men randomized to the intervention underwent PSA testing. Those with a PSA level of 3.0 ng/mL or higher underwent additional testing for high-grade prostate cancer with a 4-kallikrein panel risk score. Those with a kallikrein panel score of 7.5% or higher underwent an MRI of the prostate gland, followed by targeted biopsies for those with abnormal prostate gland MRI findings. Final data collection occurred through June 31, 2023. Main Outcomes and Measures: In descriptive exploratory analyses, the cumulative incidence of low-grade and high-grade prostate cancer after the first screening round were compared between the group invited to undergo prostate cancer screening and the control group. Results: Of 60 745 eligible men (mean [SD] age, 57.2 [4.0] years), 15 201 were randomized to be invited and 45 544 were randomized not to be invited to undergo prostate cancer screening. Of 15 201 eligible males invited to undergo screening, 7744 (51%) participated. Among them, 32 low-grade prostate cancers (cumulative incidence, 0.41%) and 128 high-grade prostate cancers (cumulative incidence, 1.65%) were detected, with 1 cancer grade group result missing. Among the 7457 invited men (49%) who refused participation, 7 low-grade prostate cancers (cumulative incidence, 0.1%) and 44 high-grade prostate cancers (cumulative incidence, 0.6%) were detected, with 7 cancer grade groups missing. For the entire invited screening group, 39 low-grade prostate cancers (cumulative incidence, 0.26%) and 172 high-grade prostate cancers (cumulative incidence, 1.13%) were detected. During a median follow-up of 3.2 years, in the group not invited to undergo screening, 65 low-grade prostate cancers (cumulative incidence, 0.14%) and 282 high-grade prostate cancers (cumulative incidence, 0.62%) were detected. The risk difference for the entire group randomized to the screening invitation vs the control group was 0.11% (95% CI, 0.03%-0.20%) for low-grade and 0.51% (95% CI, 0.33%-0.70%) for high-grade cancer. Conclusions and Relevance: In this preliminary descriptive report from an ongoing randomized clinical trial, 1 additional high-grade cancer per 196 men and 1 low-grade cancer per 909 men were detected among those randomized to be invited to undergo a single prostate cancer screening intervention compared with those not invited to undergo screening. These preliminary findings from a single round of screening should be interpreted cautiously, pending results of the study's primary mortality outcome. Trial Registration: ClinicalTrials.gov Identifier: NCT03423303 This preliminary descriptive report compares the detection rates of high-grade and low-grade prostate cancer in men invited for prostate cancer screening vs those of the control group not offered screening. Key Points: Question: What were the rates of prostate cancer detection among men randomized to be invited to undergo prostate cancer screening compared with a control group not invited to undergo screening? Findings: In this preliminary report from an ongoing clinical trial, 60 745 men aged 50 through 63 years were randomized either to be invited to undergo prostate cancer screening with a PSA test, a 4-kallikrein panel for those with a PSA of 3.0 ng/mL or higher, and MRI or not to be invited for screening (control group). The risk difference for the group invited to be screened vs the control group was 0.11% for low-grade and 0.51% for high-grade prostate cancer. Meaning: In this preliminary descriptive report, the screening intervention detected 1 high-grade prostate cancer per 196 men and 1 low-grade prostate cancer per 909 men invited to be screened. These preliminary findings should be interpreted cautiously, pending results of the study's primary outcome of prostate cancer mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Novel Peripheral Intravenous Catheter Securement for Children and Catheter Failure Reduction: A Randomized Clinical Trial.
- Author
-
Charters, Brooke, Foster, Kelly, Lawton, Benjamin, Lee, Leonard, Byrnes, Joshua, Mihala, Gabor, Cassidy, Corey, Schults, Jessica, Kleidon, Tricia M., McCaffery, Ruth, Van, Kristy, Funk, Vanessa, and Ullman, Amanda
- Published
- 2024
- Full Text
- View/download PDF
46. Basic Environmental Supports for Positive Brain and Cognitive Development in the First Year of Life.
- Author
-
Luby, Joan L., Herzberg, Max P., Hoyniak, Caroline, Tillman, Rebecca, Lean, Rachel E., Brady, Rebecca, Triplett, Regina, Alexopoulos, Dimitrios, Loseille, David, Smyser, Tara, Rogers, Cynthia E., Warner, Barbara, Smyser, Christopher D., and Barch, Deanna M.
- Published
- 2024
- Full Text
- View/download PDF
47. Cost-Effectiveness of Strategies for Treatment Timing for Perinatally Acquired Hepatitis C Virus.
- Author
-
Curtis, Megan Rose, Epstein, Rachel L., Pei, Pamela, Linas, Benjamin P., and Ciaranello, Andrea L.
- Published
- 2024
- Full Text
- View/download PDF
48. Decisional Conflict and Decision Regret in Head and Neck Oncology: A Systematic Review and Meta-Analysis.
- Author
-
Heirman, Anne Nadine, Arends, Coralie Romé, de Jel, Dominique Valérie Clarence, Dirven, Richard, van der Molen, Lisette, Halmos, Gyorgy Bela, van den Brekel, Michiel Wilhelmus Maria, and Stuiver, Martijn Matthias
- Published
- 2024
- Full Text
- View/download PDF
49. Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy.
- Author
-
Battino, Dina, Tomson, Torbjörn, Bonizzoni, Erminio, Craig, John, Perucca, Emilio, Sabers, Anne, Thomas, Sanjeev, Alvestad, Silje, Perucca, Piero, and Vajda, Frank
- Published
- 2024
- Full Text
- View/download PDF
50. Text vs Patient Portal Messaging to Improve Influenza Vaccination Coverage: A Health System–Wide Randomized Clinical Trial.
- Author
-
Szilagyi, Peter G., Duru, O. Kenrik, Casillas, Alejandra, Ong, Michael K., Vangala, Sitaram, Tseng, Chi-Hong, Albertin, Christina, Humiston, Sharon G., Clark, Emma, Ross, Mindy K., Evans, Sharon A., Sloyan, Michael, Fox, Craig R., and Lerner, Carlos
- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.